Published in Gut on February 01, 2005
Can Synbiotic Use Effect Gut Bacteria and the Immune Response in Older People | NCT01226212
Synbiotic Treatment of Ulcerative Colitis Patients | NCT00803829
Antibiotics for the Treatment of Ulcerative Colitis | NCT00355602
Synbiotic Treatment in Crohn's Disease Patients | NCT00305409
Dominant and diet-responsive groups of bacteria within the human colonic microbiota. ISME J (2010) 5.43
Two routes of metabolic cross-feeding between Bifidobacterium adolescentis and butyrate-producing anaerobes from the human gut. Appl Environ Microbiol (2006) 2.43
Polymicrobial interactions: impact on pathogenesis and human disease. Clin Microbiol Rev (2012) 2.14
Targeting the human microbiome with antibiotics, probiotics, and prebiotics: gastroenterology enters the metagenomics era. Gastroenterology (2009) 1.96
Confocal laser endomicroscopy is a new imaging modality for recognition of intramucosal bacteria in inflammatory bowel disease in vivo. Gut (2010) 1.92
Probiotics and immunity. J Gastroenterol (2009) 1.79
The human microbiome and its potential importance to pediatrics. Pediatrics (2012) 1.74
Role of the gut microbiota in defining human health. Expert Rev Anti Infect Ther (2010) 1.73
Intestinal microbiota in inflammatory bowel disease: friend of foe? World J Gastroenterol (2011) 1.65
Genomic insights into bifidobacteria. Microbiol Mol Biol Rev (2010) 1.57
Treatment of inflammatory bowel disease: a review of medical therapy. World J Gastroenterol (2008) 1.52
Ulcerative colitis and irritable bowel patients exhibit distinct abnormalities of the gut microbiota. BMC Gastroenterol (2010) 1.41
Proposed model: mechanisms of immunomodulation induced by probiotic bacteria. Clin Vaccine Immunol (2007) 1.38
The effects of short-chain fatty acids on colon epithelial proliferation and survival depend on the cellular phenotype. J Cancer Res Clin Oncol (2006) 1.36
Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis. Gut (2006) 1.36
Probiotic intervention has strain-specific anti-inflammatory effects in healthy adults. World J Gastroenterol (2008) 1.21
Anti-inflammatory effects of bifidobacteria by inhibition of LPS-induced NF-kappaB activation. World J Gastroenterol (2006) 1.21
A molecular revolution in the study of intestinal microflora. Gut (2006) 1.18
Probiotics and prebiotics in inflammatory bowel disease: microflora 'on the scope'. Br J Clin Pharmacol (2008) 1.18
Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease. Clin Exp Gastroenterol (2014) 1.17
Selection of bifidobacteria based on adhesion and anti-inflammatory capacity in vitro for amelioration of murine colitis. Appl Environ Microbiol (2010) 1.15
Effect of probiotics on pro-inflammatory cytokines and NF-kappaB activation in ulcerative colitis. World J Gastroenterol (2010) 1.14
The intestinal microbiome, probiotics and prebiotics in neurogastroenterology. Gut Microbes (2012) 1.12
Flow cytometric testing of green fluorescent protein-tagged Lactobacillus rhamnosus GG for response to defensins. Appl Environ Microbiol (2006) 1.11
Anti-inflammatory activity of probiotic Bifidobacterium: enhancement of IL-10 production in peripheral blood mononuclear cells from ulcerative colitis patients and inhibition of IL-8 secretion in HT-29 cells. World J Gastroenterol (2008) 1.09
Probiotics, prebiotics and immunomodulation of gut mucosal defences: homeostasis and immunopathology. Nutrients (2013) 1.08
Bacteria in the intestine, helpful residents or enemies from within? Infect Immun (2008) 1.07
The role of probiotic lactic acid bacteria and bifidobacteria in the prevention and treatment of inflammatory bowel disease and other related diseases: a systematic review of randomized human clinical trials. Biomed Res Int (2015) 1.07
Modulation of immunity and inflammatory gene expression in the gut, in inflammatory diseases of the gut and in the liver by probiotics. World J Gastroenterol (2014) 1.05
Longitudinal analyses of gut mucosal microbiotas in ulcerative colitis in relation to patient age and disease severity and duration. J Clin Microbiol (2012) 1.04
Intestinal microbiota: The explosive mixture at the origin of inflammatory bowel disease? World J Gastrointest Pathophysiol (2014) 1.01
The gut microbiota and inflammatory bowel disease. Semin Immunopathol (2014) 1.01
Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut. Gut Microbes (2013) 1.01
Bifidobacterium infantis strains with and without a combination of oligofructose and inulin (OFI) attenuate inflammation in DSS-induced colitis in rats. BMC Gastroenterol (2006) 1.00
Use of probiotics in gastrointestinal disorders: what to recommend? Therap Adv Gastroenterol (2010) 0.99
Kampo medicine "Dai-kenchu-to" prevents bacterial translocation in rats. Dig Dis Sci (2008) 0.98
Probiotics and prebiotics in chronic inflammatory bowel diseases. World J Gastroenterol (2006) 0.96
Characterization of the serpin-encoding gene of Bifidobacterium breve 210B. Appl Environ Microbiol (2010) 0.96
The interplay between fiber and the intestinal microbiome in the inflammatory response. Adv Nutr (2013) 0.95
An anti-inflammatory diet as treatment for inflammatory bowel disease: a case series report. Nutr J (2014) 0.92
Reduced diversity and imbalance of fecal microbiota in patients with ulcerative colitis. Dig Dis Sci (2012) 0.92
Intestinal microbiota, probiotics and prebiotics in inflammatory bowel disease. World J Gastroenterol (2014) 0.92
Why is initial bacterial colonization of the intestine important to infants' and children's health? J Pediatr Gastroenterol Nutr (2015) 0.90
Colonic involvement in Stevens-Johnson syndrome. Postgrad Med J (2006) 0.89
Probiotics increase T regulatory cells and reduce severity of experimental colitis in mice. World J Gastroenterol (2013) 0.89
Reduced diversity and altered composition of the gut microbiome in individuals with myalgic encephalomyelitis/chronic fatigue syndrome. Microbiome (2016) 0.88
Prebiotics in chronic intestinal inflammation. Inflamm Bowel Dis (2009) 0.88
Remission induction and maintenance effect of probiotics on ulcerative colitis: a meta-analysis. World J Gastroenterol (2010) 0.88
A two-component regulatory system controls autoregulated serpin expression in Bifidobacterium breve UCC2003. Appl Environ Microbiol (2012) 0.87
Synbiotics decrease the incidence of septic complications in patients with severe SIRS: a preliminary report. Dig Dis Sci (2008) 0.87
Effect of oral administration of Butyrivibrio fibrisolvens MDT-1 on experimental enterocolitis in mice. Clin Vaccine Immunol (2006) 0.87
Meta-analysis of the placebo response in ulcerative colitis. Dig Dis Sci (2007) 0.86
Upregulation of P-glycoprotein by probiotics in intestinal epithelial cells and in the dextran sulfate sodium model of colitis in mice. Am J Physiol Gastrointest Liver Physiol (2011) 0.86
Probiotics, prebiotics, synbiotics: ecological treatment for inflammatory bowel disease? Gut (2006) 0.86
Nutritional modulators of ulcerative colitis: clinical efficacies and mechanistic view. World J Gastroenterol (2013) 0.86
Adherence and cytokine induction in Caco-2 cells by bacterial populations from a three-stage continuous-culture model of the large intestine. Appl Environ Microbiol (2011) 0.85
Pathobiology and potential therapeutic value of intestinal short-chain fatty acids in gut inflammation and obesity. Dig Dis Sci (2013) 0.85
Micronutrients, N-acetyl cysteine, probiotics and prebiotics, a review of effectiveness in reducing HIV progression. Nutrients (2010) 0.85
Probiotics in inflammatory bowel diseases and associated conditions. Nutrients (2011) 0.85
The yin and yang of bacterial resilience in the human gut microbiota. J Mol Biol (2014) 0.84
Probiotics and inflammatory bowel diseases. Postgrad Med J (2006) 0.84
Bifidobacterium longum CCM 7952 Promotes Epithelial Barrier Function and Prevents Acute DSS-Induced Colitis in Strictly Strain-Specific Manner. PLoS One (2015) 0.82
Do probiotics have a therapeutic role in gastroenterology? World J Gastroenterol (2006) 0.82
Actual concept of "probiotics": is it more functional to science or business? World J Gastroenterol (2013) 0.82
Determination of the discriminant score of intestinal microbiota as a biomarker of disease activity in patients with ulcerative colitis. BMC Gastroenterol (2014) 0.82
Emergent Sources of Prebiotics: Seaweeds and Microalgae. Mar Drugs (2016) 0.82
In vivo selection to identify bacterial strains with enhanced ecological performance in synbiotic applications. Appl Environ Microbiol (2015) 0.81
A review of the pharmacobiotic regulation of gastrointestinal inflammation by probiotics, commensal bacteria and prebiotics. Inflammopharmacology (2012) 0.80
The Effect of Campylobacter concisus on Expression of IL-18, TNF-α and p53 in Barrett's Cell Lines. Jundishapur J Microbiol (2015) 0.80
The hygiene hypothesis: current perspectives and future therapies. Immunotargets Ther (2015) 0.79
Effects of prebiotics on immune system and cytokine expression. Med Microbiol Immunol (2016) 0.79
Modulating Composition and Metabolic Activity of the Gut Microbiota in IBD Patients. Int J Mol Sci (2016) 0.79
Microbial biofilms and gastrointestinal diseases. Pathog Dis (2013) 0.79
Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis. World J Gastroenterol (2015) 0.79
Carbohydrate Elimination or Adaptation Diet for Symptoms of Intestinal Discomfort in IBD: Rationales for "Gibsons' Conundrum". Int J Inflam (2012) 0.79
Probiotics and the gastrointestinal tract: where are we in 2005? World J Gastroenterol (2006) 0.79
Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders. Br J Pharmacol (2016) 0.78
Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies. Clin Microbiol Rev (2017) 0.78
Oligomannan Prebiotic Attenuates Immunological, Clinical and Behavioral Symptoms in Mouse Model of Inflammatory Bowel Disease. Sci Rep (2016) 0.78
Using corticosteroids to reshape the gut microbiome: implications for inflammatory bowel diseases. Inflamm Bowel Dis (2015) 0.77
Probiotics in the management of inflammatory bowel disease. MedGenMed (2005) 0.77
Impact of Probiotic Administration on Serum C-Reactive Protein Concentrations: Systematic Review and Meta-Analysis of Randomized Control Trials. Nutrients (2017) 0.77
Probiotic Bifidobacterium species: potential beneficial effects in diarrheal disorders. Focus on "Probiotic Bifidobacterium species stimulate human SLC26A3 gene function and expression in intestinal epithelial cells". Am J Physiol Cell Physiol (2014) 0.76
Active hexose-correlated compound and Bifidobacterium longum BB536 exert symbiotic effects in experimental colitis. Eur J Nutr (2012) 0.76
Use of pre-, pro- and synbiotics in patients with acute pancreatitis: a meta-analysis. World J Gastroenterol (2010) 0.76
Microbial-Derived 1,4-Dihydroxy-2-naphthoic Acid and Related Compounds as Aryl Hydrocarbon Receptor Agonists/Antagonists: Structure-Activity Relationships and Receptor Modeling. Toxicol Sci (2016) 0.75
Probiotics, prebiotics, synbiotics and naturally fermented foods: why more may be more. Ann Gastroenterol (2013) 0.75
The emerging therapeutic role of probiotics in inflammatory bowel disease. Gastroenterol Hepatol (N Y) (2008) 0.75
Synbiotic therapy for ulcerative colitis. Gut (2005) 0.75
Clinical Evidence for the Microbiome in Inflammatory Diseases. Front Immunol (2017) 0.75
The ecological community of commensal, symbiotic, and pathogenic gastrointestinal microorganisms - an appraisal. Clin Exp Gastroenterol (2017) 0.75
Modulation of Gut Microbiome Composition and Function in Experimental Colitis Treated with Sulfasalazine. Front Microbiol (2017) 0.75
Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell (1991) 13.70
Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell (1993) 11.95
Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat Immunol (2001) 11.07
VARIATION BETWEEN OBSERVERS IN DESCRIBING MUCOSAL APPEARANCES IN PROCTOCOLITIS. Br Med J (1964) 7.02
The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med (1994) 5.46
Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet (1999) 5.36
Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD) Clin Exp Immunol (1995) 4.81
Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology (2003) 4.40
A simple clinical colitis activity index. Gut (1998) 4.35
Widespread expression of beta-defensin hBD-1 in human secretory glands and epithelial cells. FEBS Lett (1996) 3.39
Expression and regulation of the human beta-defensins hBD-1 and hBD-2 in intestinal epithelium. J Immunol (1999) 3.39
Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther (1997) 3.02
Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut (2004) 3.01
Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study. Gastroenterology (1998) 2.62
The intestinal mucus layer from patients with inflammatory bowel disease harbors high numbers of bacteria compared with controls. Gastroenterology (1999) 2.37
Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci (2000) 2.26
Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther (1999) 2.26
Inducible and constitutive beta-defensins are differentially expressed in Crohn's disease and ulcerative colitis. Inflamm Bowel Dis (2003) 2.06
Bacteria as the cause of ulcerative colitis. Gut (2001) 1.96
Increased mucosal tumour necrosis factor alpha production in Crohn's disease can be downregulated ex vivo by probiotic bacteria. Gut (2002) 1.94
The dendritic cell: its role in intestinal inflammation and relationship with gut bacteria. Gut (2003) 1.84
Crohn's disease: a defensin deficiency syndrome? Eur J Gastroenterol Hepatol (2003) 1.72
Recent developments in the immunology of inflammatory bowel disease. Scand J Immunol (2000) 1.69
Identification of multiple novel epididymis-specific beta-defensin isoforms in humans and mice. J Immunol (2002) 1.53
Mucosa-associated bacterial flora of the human colon. J Med Microbiol (1997) 1.47
Regulation of human beta-defensins by gastric epithelial cells in response to infection with Helicobacter pylori or stimulation with interleukin-1. Infect Immun (2000) 1.33
Chemotaxonomic analysis of bacterial populations colonizing the rectal mucosa in patients with ulcerative colitis. Clin Infect Dis (2004) 1.33
Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis. Gut (1985) 1.28
Prebiotics and synbiotics: concepts and nutritional properties. Br J Nutr (1998) 1.24
The rectal mucosa-associated microflora in patients with ulcerative colitis. J Med Microbiol (1992) 1.24
Use of probiotics in the treatment of inflammatory bowel disease. J Clin Gastroenterol (2003) 1.21
Characterization of antibody responses against rectal mucosa-associated bacterial flora in patients with ulcerative colitis. J Gastroenterol Hepatol (2000) 1.21
Probiotics, infection and immunity. Curr Opin Infect Dis (2002) 1.07
Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. Am J Gastroenterol (1994) 1.06
Human intestinal epithelial cells secrete interleukin-1 receptor antagonist and interleukin-8 but not interleukin-1 or interleukin-6. Gut (2000) 1.02
Mucosal cytokine expression, cellular markers and adhesion molecules in inflammatory bowel disease. Eur J Gastroenterol Hepatol (1999) 1.02
Regulation of expression of beta-defensins: endogenous enteric peptide antibiotics. Mol Immunol (2003) 0.97
A study of fructo oligosaccharides in the prevention of travellers' diarrhoea. Aliment Pharmacol Ther (2001) 0.88
Assessment of mucosal inflammation and circulation in response to probiotics in patients operated with ileal pouch anal anastomosis for ulcerative colitis. Scand J Gastroenterol (2003) 0.86
Ciprofloxacin as a treatment for ulcerative colitis-not yet. Gastroenterology (1998) 0.83
The use of statins: a case of misleading priorities? BMJ (1997) 13.35
Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut (1987) 6.61
Factors which influence necropsy requests: a psychological approach. J Clin Pathol (1992) 5.25
Classification and measurement of nutritionally important starch fractions. Eur J Clin Nutr (1992) 4.84
The control and consequences of bacterial fermentation in the human colon. J Appl Bacteriol (1991) 4.29
Measurement of the mean transit time of dietary residue through the human gut. Gut (1976) 4.22
Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology (2006) 4.06
Short chain fatty acids in the human colon. Gut (1981) 3.49
Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology (2009) 3.49
Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin. Gastroenterology (1995) 3.26
Short chain fatty acid absorption by the human large intestine. Gut (1978) 2.87
Comparison of fermentation reactions in different regions of the human colon. J Appl Bacteriol (1992) 2.87
Functional food science and gastrointestinal physiology and function. Br J Nutr (1998) 2.78
Occurrence of sulphate-reducing bacteria in human faeces and the relationship of dissimilatory sulphate reduction to methanogenesis in the large gut. J Appl Bacteriol (1988) 2.71
Intakes and sources of dietary fiber in the British population. Am J Clin Nutr (1979) 2.58
Paclitaxel administration to gynecologic cancer patients with major cardiac risk factors. J Clin Oncol (1998) 2.45
Transit through the gut measured by analysis of a single stool. Gut (1976) 2.36
Production, metabolism, and excretion of hydrogen in the large intestine. Gastroenterology (1992) 2.34
Colonic response to dietary fibre from carrot, cabbage, apple, bran. Lancet (1978) 2.33
Neutrophil transmigration in inflammatory bowel disease is associated with differential expression of epithelial intercellular junction proteins. Am J Pathol (2001) 2.31
The microbial contribution to human faecal mass. J Med Microbiol (1980) 2.26
Changes in predominant bacterial populations in human faeces with age and with Clostridium difficile infection. J Med Microbiol (2002) 2.18
Alternative pathways for hydrogen disposal during fermentation in the human colon. Gut (1990) 2.13
A randomised controlled trial of self-help interventions in patients with a primary care diagnosis of irritable bowel syndrome. Gut (2005) 2.11
The effect of meat protein and dietary fiber on colonic function and metabolism. II. Bacterial metabolites in feces and urine. Am J Clin Nutr (1979) 2.06
Starch utilization by the human large intestinal microflora. J Appl Bacteriol (1986) 2.05
Sulphate reducing bacteria and hydrogen metabolism in the human large intestine. Gut (1993) 2.05
Pediatric acute myeloid leukemia with NPM1 mutations is characterized by a gene expression profile with dysregulated HOX gene expression distinct from MLL-rearranged leukemias. Leukemia (2007) 2.04
Competition for hydrogen between sulphate-reducing bacteria and methanogenic bacteria from the human large intestine. J Appl Bacteriol (1988) 1.97
Saving lives on roads. Lancet (1994) 1.95
Changes in fecal composition and colonic function due to cereal fiber. Am J Clin Nutr (1976) 1.91
Bacterial metabolism and health-related effects of galacto-oligosaccharides and other prebiotics. J Appl Microbiol (2008) 1.91
Protein degradation by human intestinal bacteria. J Gen Microbiol (1986) 1.90
Determination of the non-starch polysaccharides in plant foods by gas-liquid chromatography of constituent sugars as alditol acetates. Analyst (1982) 1.89
Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol (1999) 1.87
Metabolism of dietary sulphate: absorption and excretion in humans. Gut (1991) 1.85
Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy. Invest Ophthalmol Vis Sci (1997) 1.81
Carbohydrate fermentation in the human colon and its relation to acetate concentrations in venous blood. J Clin Invest (1985) 1.77
Dietary fibre. Gut (1973) 1.77
Risk-perception: differences between adolescents and adults. Health Psychol (1995) 1.76
Urine nitrogen as an independent validatory measure of dietary intake: a study of nitrogen balance in individuals consuming their normal diet. Am J Clin Nutr (1985) 1.75
Insulin control of glycogen metabolism in knockout mice lacking the muscle-specific protein phosphatase PP1G/RGL. Mol Cell Biol (2001) 1.73
Enumeration of human colonic bacteria producing phenolic and indolic compounds: effects of pH, carbohydrate availability and retention time on dissimilatory aromatic amino acid metabolism. J Appl Bacteriol (1996) 1.72
Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology (2009) 1.70
What are the health benefits of physical activity in type 1 diabetes mellitus? A literature review. Diabetologia (2011) 1.67
Fermentation in the human large intestine and the available substrates. Am J Clin Nutr (1987) 1.67
An aldose reductase inhibitor and aminoguanidine prevent vascular endothelial growth factor expression in rats with long-term galactosemia. Arch Ophthalmol (1997) 1.66
General practitioners, skin lesions and the new contract. J Public Health Med (1992) 1.66
Electrospray ionization mass spectrometry analysis of lysophospholipids in human ascitic fluids: comparison of the lysophospholipid contents in malignant vs nonmalignant ascitic fluids. Anal Biochem (2001) 1.65
Does increased endogenous formation of N-nitroso compounds in the human colon explain the association between red meat and colon cancer? Carcinogenesis (1996) 1.65
The contribution of sulphate reducing bacteria and 5-aminosalicylic acid to faecal sulphide in patients with ulcerative colitis. Gut (2000) 1.65
Probiotics and prebiotics: can regulating the activities of intestinal bacteria benefit health? BMJ (1999) 1.65
Identification and quantitation of mucosal and faecal desulfovibrios using real time polymerase chain reaction. Gut (2004) 1.63
Prebiotic digestion and fermentation. Am J Clin Nutr (2001) 1.62
FAO/WHO scientific update on carbohydrates in human nutrition: conclusions. Eur J Clin Nutr (2007) 1.60
Review article: prebiotics in the gastrointestinal tract. Aliment Pharmacol Ther (2006) 1.59
Role of the colon in ileal-resection diarrhoea. Lancet (1973) 1.58
Digestion of polysaccharides of potato in the small intestine of man. Am J Clin Nutr (1987) 1.58
Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity. Gynecol Oncol (1996) 1.57
Mechanism of action of dietary fibre in the human colon. Nature (1980) 1.57
The use of 4-aminobenzoic acid as a marker to validate the completeness of 24 h urine collections in man. Clin Sci (Lond) (1983) 1.56
Laxative abuse. Gut (1974) 1.54
Synbiotic consumption changes the metabolism and composition of the gut microbiota in older people and modifies inflammatory processes: a randomised, double-blind, placebo-controlled crossover study. Aliment Pharmacol Ther (2013) 1.54
Role of intestinal bacteria in nutrient metabolism. JPEN J Parenter Enteral Nutr (1998) 1.54
Use of a three-stage continuous culture system to study the effect of mucin on dissimilatory sulfate reduction and methanogenesis by mixed populations of human gut bacteria. Appl Environ Microbiol (1988) 1.53
Digestion of the carbohydrates of banana (Musa paradisiaca sapientum) in the human small intestine. Am J Clin Nutr (1986) 1.52
Hydrogen sulphide: a bacterial toxin in ulcerative colitis? Gut (1996) 1.52
Breath methane and large bowel cancer risk in contrasting African populations. Gut (1988) 1.50
Effect of black tea drinking on blood lipids, blood pressure and aspects of bowel habit. Br J Nutr (1997) 1.48
Effect of changing transit time on colonic microbial metabolism in man. Gut (1987) 1.47
Fermentation in the human large intestine: evidence and implications for health. Lancet (1983) 1.46
The effect of age, sex and level of intake of dietary fibre from wheat on large-bowel function in thirty healthy subjects. Br J Nutr (1986) 1.44
Pleural involvement in the carcinoid syndrome. Q J Med (1993) 1.42
Variation in human intestinal microbiota with age. Dig Liver Dis (2002) 1.41
Prebiotic carbohydrates modify the mucosa associated microflora of the human large bowel. Gut (2004) 1.41
Necrotizing granulomas of the peritoneum. Histopathology (1991) 1.40
Revision of the 1990 working formulation for cardiac allograft rejection: the Sheffield experience. Heart (1998) 1.40
Colonic microflora: nutrition and health. Nutrition (1997) 1.39
Immunoalkaline phosphatase technique applied to paraffin wax embedded tissues in diagnostic renal pathology. J Clin Pathol (1990) 1.38
Human colonic microbiota: ecology, physiology and metabolic potential of intestinal bacteria. Scand J Gastroenterol Suppl (1997) 1.37
'Flicker' on VDU screens. Nature (1993) 1.37
Contribution of dietary protein to sulfide production in the large intestine: an in vitro and a controlled feeding study in humans. Am J Clin Nutr (2000) 1.35
Intestinal bacteria and ulcerative colitis. Curr Issues Intest Microbiol (2003) 1.35
Effect of intravenous prostaglandin F 2 on small intestinal function in man. Nature (1973) 1.35
Inflammatory disease processes and interactions with nutrition. Br J Nutr (2009) 1.34
Influence of diets high and low in animal fat on bowel habit, gastrointestinal transit time, fecal microflora, bile acid, and fat excretion. J Clin Invest (1978) 1.32
Digestion of the polysaccharides of some cereal foods in the human small intestine. Am J Clin Nutr (1985) 1.31
Starch intake and colorectal cancer risk: an international comparison. Br J Cancer (1994) 1.29